BR112022018515A2 - Terapia de combinação para leucemia mieloide aguda - Google Patents

Terapia de combinação para leucemia mieloide aguda

Info

Publication number
BR112022018515A2
BR112022018515A2 BR112022018515A BR112022018515A BR112022018515A2 BR 112022018515 A2 BR112022018515 A2 BR 112022018515A2 BR 112022018515 A BR112022018515 A BR 112022018515A BR 112022018515 A BR112022018515 A BR 112022018515A BR 112022018515 A2 BR112022018515 A2 BR 112022018515A2
Authority
BR
Brazil
Prior art keywords
combination therapy
myeloid leukemia
acute myeloid
difluoroacetamide
dioxopiperidin
Prior art date
Application number
BR112022018515A
Other languages
English (en)
Inventor
J Buchholz Tonia
Gong Nian
Fan Jinhong
Pace Emily
W Pierce Daniel
POURDEHNAD Michael
Yao Tsun-Wen
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112022018515A2 publication Critical patent/BR112022018515A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TERAPIA DE COMBINAÇÃO PARA LEUCEMIA MIELOIDE AGUDA. A presente invenção refere-se a métodos de tratamento de LMA que compreendem a administração de 2-(4-clorofenil)-N-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida ou um estereoisômero ou mistura de estereoisômeros, sal farmaceuticamente aceitável, tautômero, profármaco, solvato, hidrato, cocristal, clatrato ou polimorfo da mesma em uma terapia de combinação.
BR112022018515A 2020-03-16 2021-03-12 Terapia de combinação para leucemia mieloide aguda BR112022018515A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990372P 2020-03-16 2020-03-16
PCT/US2021/022182 WO2021188387A1 (en) 2020-03-16 2021-03-12 Combination therapy for acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BR112022018515A2 true BR112022018515A2 (pt) 2022-11-16

Family

ID=77772140

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018515A BR112022018515A2 (pt) 2020-03-16 2021-03-12 Terapia de combinação para leucemia mieloide aguda

Country Status (11)

Country Link
US (1) US20230149379A1 (pt)
EP (1) EP4121051A4 (pt)
JP (1) JP2023520177A (pt)
KR (1) KR20220154175A (pt)
CN (1) CN115515582A (pt)
AU (1) AU2021239822A1 (pt)
BR (1) BR112022018515A2 (pt)
CA (1) CA3171588A1 (pt)
IL (1) IL296557A (pt)
MX (1) MX2022011523A (pt)
WO (1) WO2021188387A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006133A (es) 2019-12-06 2022-06-17 Celgene Corp Procesos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin- 3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
WO2023154904A2 (en) * 2022-02-11 2023-08-17 Loma Linda University Compositions and methods for treating acute myeloid leukemia
WO2024091959A1 (en) * 2022-10-24 2024-05-02 The Regents Of The University Of California Drug resistant immune cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008421A (es) * 2016-01-08 2019-12-09 Celgene Corp Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2018015120A (es) * 2016-06-06 2019-04-15 Celgene Corp Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida.
HUE061356T2 (hu) * 2017-06-30 2023-06-28 Celgene Corp 2-(4-klórfenil)-N-((2-(2,6-dioxopiperidin-3-il)-1-oxoizoindolin-5-il)metil)-2,2--difluoracetamidot tartalmazó készítmények és eljárások ezek alkalmazására

Also Published As

Publication number Publication date
MX2022011523A (es) 2022-12-13
US20230149379A1 (en) 2023-05-18
AU2021239822A1 (en) 2022-10-13
IL296557A (en) 2022-11-01
EP4121051A4 (en) 2024-04-17
KR20220154175A (ko) 2022-11-21
CN115515582A (zh) 2022-12-23
CA3171588A1 (en) 2021-09-23
EP4121051A1 (en) 2023-01-25
WO2021188387A1 (en) 2021-09-23
JP2023520177A (ja) 2023-05-16

Similar Documents

Publication Publication Date Title
BR112022018515A2 (pt) Terapia de combinação para leucemia mieloide aguda
BR112023001195A2 (pt) Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
ECSP18051143A (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
MX2022003130A (es) Derivado de hidrazina ciclica sustituida con ciano y aplicacion del mismo.
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
NZ778087A (en) Pyrrolopyrimidine derivative and use thereof
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CL2022002641A1 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
CO2021016295A2 (es) Compuestos de pirrolidina
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
MX2023003825A (es) Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.
BR112018074612A2 (pt) forma cristalina de composto que suprimir a atividade de proteína quinase e aplicação da mesma
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
UY39799A (es) Compuestos de pirrolil–sulfonamida
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing